<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="85755">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02002650</url>
  </required_header>
  <id_info>
    <org_study_id>20131106-7</org_study_id>
    <secondary_id>20131106-7</secondary_id>
    <nct_id>NCT02002650</nct_id>
  </id_info>
  <brief_title>Rectal Indomethacin to Prevent Post-ERCP Pancreatitis</brief_title>
  <acronym>Indomethacin</acronym>
  <official_title>A Prospective, Randomized, Controlled Trial of Pre-operational Rectal Indomethacin in the Prevention of Post-ERCP Pancreatitis in Average-risk Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fourth Military Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fourth Military Medical University</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute pancreatitis is the most common and feared complication of ERCP, occurring after 1% to
      30% of procedures. A number of trials have evaluated that rectal NSAIDs (non-steroidal
      anti-inflammatory drug) can prevent post-ERCP pancreatitis (PEP) in high risk patients.
      However, the risk factors of PEP is not fully clear. Rectal indomethacin before ERCP for all
      patients, not just for selected high-risk factor patients, may preventing the PEP maximum.
      The purpose of this study is to determine whether routine using of rectal indomethacin is
      more effective than the conditional regimen.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Post-ERCP Pancreatitis</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Subjects were diagnosed with post-ERCP pancreatitis if they experienced new upper abdominal pain, serum amylase elevation at least three times the upper limit of normal 24 hours after the procedure, and hospitalization prolonged at least two nights.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of pancreatitis</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>Post-ERCP Acute Pancreatitis</condition>
  <arm_group>
    <arm_group_label>Pre-operational group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-operational rectal Indomethacin for all patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Post-operational group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Post-operational rectal Indomethacin for high-risk patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pre-operational rectal Indomethacin</intervention_name>
    <description>Rectal Indomethacin was administrated 30min to 60min before ERCP for all patients.</description>
    <arm_group_label>Pre-operational group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Post-operational Rectal Indomethacin</intervention_name>
    <description>Rectal Indomethacin was administrated immediately after ERCP just for high-risk patients.</description>
    <arm_group_label>Post-operational group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing diagnostic or therapeutic ERCP.

        Exclusion Criteria:

          -  Unwillingness or inability to consent for the study;

          -  Age &lt; 18 years old;

          -  Intrauterine pregnancy;

          -  Breastfeeding mother;

          -  Standard contraindications to ERCP;

          -  Allergy to NSAIDs;

          -  Received NSAIDs in prior 7 days;

          -  Renal failure (Cr &gt;1.4mg/dl=120umol/l);

          -  Active or recurrent (within 4 weeks) gastrointestinal hemorrhage;

          -  Acute pancreatitis within 72 hours;

          -  Known chronic calcific pancreatitis, pancreatic divisum or pancreatic head mass;

          -  Subject with prior biliary sphincterotomy now scheduled for repeat biliary therapy
             without anticipated pancreatogram;

          -  ERCP for biliary stent removal or exchange without anticipated pancreatogram;

          -  Known active cardiovascular or cerebrovascular disease.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanglin Pan, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Xijing Hospital of Digestive Diseases.The Fourth Military Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yanglin Pan, M.D.</last_name>
    <phone>86-29-84771536</phone>
    <email>panyl@fmmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hui Luo, M.D.</last_name>
    <phone>86-29-84771536</phone>
    <email>fmmulh@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Hospital of Lanzhou University</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <zip>730000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wence Zhou, M.D.</last_name>
      <email>zhouwc129@163.com</email>
    </contact>
    <investigator>
      <last_name>Wence Zhou, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General Hospital of NingXia Medical University</name>
      <address>
        <city>Yinchuan</city>
        <state>Ningxia</state>
        <zip>750004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qi Wang, M.D.</last_name>
      <phone>8613895098592</phone>
      <email>wq-6562@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Ming Li, M.D.</last_name>
      <phone>8613519216501</phone>
      <email>nyfygdwk@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ming Li, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xijing Hospital of Digestive Diseases</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanglin Pan, M.D.</last_name>
      <phone>86-29-84771536</phone>
      <email>panyl@fmmu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Hui Luo, M.D.</last_name>
      <phone>86-29-84771536</phone>
      <email>fmmulh@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Hui Luo, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital Of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hao Sun, M.D.</last_name>
      <phone>862985323905</phone>
      <email>Sunhaoxjyf@126.com</email>
    </contact>
    <investigator>
      <last_name>Hao Sun, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>No. 451 Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710054</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi Zhou, M.D.</last_name>
      <phone>8613399289251</phone>
      <email>Zhouyi02192005@aliyun.com</email>
    </contact>
    <investigator>
      <last_name>Yi Zhou, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urumqi General Hospital of Lanzhou Military Region</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang</state>
        <zip>830002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhan Guo, M.D.</last_name>
      <phone>8613999116558</phone>
      <email>niezg@vip.sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Ting Lei, M.D.</last_name>
      <phone>8618999838871</phone>
      <email>lting.xj@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ting Lei, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Ding X, Chen M, Huang S, Zhang S, Zou X. Nonsteroidal anti-inflammatory drugs for prevention of post-ERCP pancreatitis: a meta-analysis. Gastrointest Endosc. 2012 Dec;76(6):1152-9. doi: 10.1016/j.gie.2012.08.021.</citation>
    <PMID>23164513</PMID>
  </results_reference>
  <results_reference>
    <citation>Elmunzer BJ, Scheiman JM, Lehman GA, Chak A, Mosler P, Higgins PD, Hayward RA, Romagnuolo J, Elta GH, Sherman S, Waljee AK, Repaka A, Atkinson MR, Cote GA, Kwon RS, McHenry L, Piraka CR, Wamsteker EJ, Watkins JL, Korsnes SJ, Schmidt SE, Turner SM, Nicholson S, Fogel EL; U.S. Cooperative for Outcomes Research in Endoscopy (USCORE). A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med. 2012 Apr 12;366(15):1414-22.</citation>
    <PMID>22494121</PMID>
  </results_reference>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 6, 2013</lastchanged_date>
  <firstreceived_date>December 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fourth Military Medical University</investigator_affiliation>
    <investigator_full_name>Yanglin Pan</investigator_full_name>
    <investigator_title>Associated professor</investigator_title>
  </responsible_party>
  <keyword>Indomethacin, pancreatitis, ERCP</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pancreatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Indomethacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
